It is well-known that unhealthy diet and sedentary lifestyle leads to obesity. With, globalization and adaptation of the Western-style (fast food) diet, obesity has become a global epidemic problem. In turn, obesity causes a wide variety of diseases such as cardiovascular, diabetes, hypertension, etc. which can ultimately lead to renal failure. The cost associated with the treatment of chronic kidney disease has placed a heavy burden on the global healthcare budget. By the time CKD is detected, renal failure has progressed to CKD Stages III or IV, and ultimately leading to Stage V (ESRD) requiring dialysis or renal transplant. In the USA dialysis costs the government’s healthcare budget approximately $35 Billion for about 600,000 patients. Our 20 year old company has been involved in developing a novel probiotic and prebiotic (synbiotic) dietary supplement which helps to maintain healthy kidney function by modulation of the gut microbiome, thus potentially delaying the progression of CKD to Stage V (ESRD). The product Renadyl™ has been developed with a pharma-like validation specifically targeted towards CKD stage III and IV based on the technological concept of “Enteric Dialysis®” for removal of various uremic toxins thus restoring gut dysbiosis. This oral product is safe, efficacious, and easy to use for renal patients worldwide. It can be used in conjunction with any standard care of therapy for CKD applications globally.
Dr. Natarajan Ranganathan, PhD, (Dr. Rangan) is the key founder and Managing Director (R&D) of Kibow Biotech, Inc a pioneering company in the field of understanding the Gut Microbiome, Dysbiosis, and its stabilization with Probiotics and Prebiotics towards health, disease and healing processes. As a medical R&D professional, Dr. Rangan brings significant professional expertise and knowledge related to various medical specialties specifically in connecting mind-body, Gut-Brain, Gut-Kidney and integrated holistic medical fields. For the past four decades, in his role as a medical R&D professional specializing in the clinical utility of probiotics towards Chronic Kidney Disease and related applications, Dr. Rangan has gained significant professional expertise and has become a respected and sought after speaker at various scientific events in addition to a requested peer reviewer for various medical journals.
He obtained dual master’s degrees (organic chemistry and biochemistry) from the University Of Poona, India and earned his doctoral degree in Bio-organic chemistry from Temple University, Philadelphia. He received further academic training at the University of Pennsylvania, Hahnemann Medical College, Philadelphia, and Johns Hopkins Medical Institutions, Baltimore.
Usha Vyas, MSc, is a senior microbiologist at Kibow Biotech Inc, which develops probiotic dietary supplements. She earned her Master’s Degree in Microbiology from India and received two gold medals for standing first in the university in Chemistry at the undergraduate level. Her career as a microbiologist began with Alembic Limited, a generic pharmaceutical company in India where she worked in the fermentation R&D labs with industrial bacteria which produce important drugs like Erythromycin, Tacrolimus, Lovastatin and Penicillin. During her 22 year tenure with Alembic she published two patents. In her capacity as a Manager and Head Scientist she worked with cross functional teams and groups from R&D to manufacturing, quality control and marketing and was heading the fermentation labs. Her present work at Kibow involves R&D of new probiotic formulations for various applications; oversees quality control for current products and manages lab operations. For last 7 years she has been speaking at various forums to Renal Dieticians and Nephrology nurses and other health care professionals educating them on the concept and importance of probiotics in health and disease and the modulation of the gut microbiome.
Kevin Hanlon, BSc Biology, is a research associate at Kibow Biotech Inc., which manufactures a wide variety of probiotic and prebiotic supplements spanning a wide range of human health. He is currently pursuing a Master’s degree in Biotechnology at Temple University, in Philadelphia. During his brief career at Kibow Biotech, he has been involved in researching new avenues for application of probiotics, conducting quality control tests, and speaking with healthcare professionals about the product line.